Please login to the form below
kidney disease
This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.
Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
Fabry disease is a rare disorder in which patients inherit a deficiency of the α–Galactosidase–A enzyme. ... Fabry disease is a rare inherited disorder. Patients inherit a deficiency of the α–Galactosidase–A enzyme that results in the breakdown
Latest news
-
Bayer’s finerenone scores FDA priority review for chronic kidney disease
Bayer has scored a US Food and Drug Administration (FDA) priority review for its investigational drug finerenone for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). ... Overactivation of the mineralocorticoid receptor is believed to
-
AZ’s Farxiga cuts risk of death in chronic kidney disease
AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of Cardiology (ESC) virtual ... It is often caused by diabetes, hypertension and
-
Calliditas bets on PBC drug in Genkyotex buyout
The drug is also being evaluated in a phase 2 clinical trial in type 1 diabetes and kidney disease, and a further phase 2 trial of the drug in IPF is ... Genkyotex’s platform identifies small molecules which can selectively inhibit specific NOX enzymes
-
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial
Earlier this week, AZ also touted results for Farxiga in kidney disease, after the drug reduced kidney disease progression in a phase 3 trial of patients with chronic kidney disease ... In March, the US Food and Drug Administration (FDA) gave Jardiance
-
Gilead swoops on Forty Seven with $4.9bn all-cash deal
It also signed a $2.35bn deal with Nurix for protein degradation drugs for cancer and other diseases, and a $2bn alliance with Goldfinch Bio in the kidney disease area, continuing
More from news
Approximately 22 fully matching, plus 142 partially matching documents found.
Latest Intelligence
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care. ... AstraZeneca's R&D centre in Cambridge, UK. Moderate to severe chronic kidney disease (CKD) is an under-recognised public health
-
Cortellis Drugs to Watch in 2020 report
4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD). ... Hypercholesterolemia is a major risk of
-
Case study: What we're made of
If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple
-
25 Women Leaders in UK Healthcare
The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Sanifit appoints Alexander Gold chief medical officer
Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
However, once these trials are divided up into specific diseases the underrepresentation becomes clearer, especially in the fields of cardiovascular diseases, hepatitis, HIV, chronic kidney disease and digestive diseases.
-
Are biobetters a market access opportunity?
Mircera, used in the treatment of anaemia in Chronic Kidney Disease (CKD), was approved in 2007 by the European Medicines Agency (EMA) for once-monthly dosing as opposed to weekly dosing ... Ensuring market access for biobetters. Biobetters provide
-
Virtual Research Grants Submission and Approval Program
Our client’s main objectives were to:. Establish an independent review committee comprising experienced nephrologists and academics specializing in research related to kidney disease.
-
Addressing Climate Impact: The Healthcare Paradox
In 2018 there were 220 million more heatwave exposures affecting older populations increasing risks of heart and kidney stress and disease and stroke.
-
Its Know Your Numbers week
One in 4 adults in the UK has high blood pressure so the risk of developing heart disease, heart attacks, strokes, kidney disease and vascular dementia are very real. ... Lack of exercise. Being overweight. Chronic Kidney Disease. Regularly drinking
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Content Editor - Biotechnology
-
Salary TBC
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
- Saturnino Izquierdo takes on expanded role at McCann Health
- J&J delays EU COVID-19 vaccine rollout following pause in the US
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- UK trial evaluating mixed-vaccine regimens includes two more jabs
- Follow the user – democratising medical conference design
PMHub
Madmicrobe Studios
MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...
Latest intelligence
- How a design mindset can lead to better medical outcomes
- By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
- How does the government plan to reshape the NHS?
- Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
- Want to give perfect client service? Tough luck, you’re human
- In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
Quick links
Infographics
